Why this drug is interesting
Midazolam is water-soluble at the acidic pH of the ampoule and lipid-soluble at physiological pH — a chemical trick that gives it a painless injection and rapid brain penetration. It is amnestic, anxiolytic, anticonvulsant and sedative, and it has been the workhorse of procedural sedation for decades.
It is also the drug for which the SmPC opens its posology section with an unusual instruction: "Midazolam is a potent sedative agent that requires titration and slow administration."1 Labels do not usually feel the need to say this. This one does, because the harm from midazolam is almost entirely a harm of giving too much too quickly to the wrong patient.
Dosing
| Indication | Adults <60 years | Adults ≥60 / debilitated / chronically ill |
|---|---|---|
| Conscious sedation | Initial 2–2.5 mg; titration doses 1 mg; total 3.5–7.5 mg | Initial 0.5–1 mg; titration doses 0.5–1 mg; total <3.5 mg |
| Anaesthesia premedication | IV 1–2 mg repeated; IM 0.07–0.1 mg/kg | IV initial 0.5 mg, slow uptitration; IM 0.025–0.05 mg/kg |
| Anaesthesia induction | 0.15–0.2 mg/kg (0.3–0.35 without premedication) | 0.05–0.15 mg/kg (0.15–0.3 without premedication) |
| Sedative component in combined anaesthesia | 0.03–0.1 mg/kg intermittently, or 0.03–0.1 mg/kg/h | Lower doses than for adults under 60 |
| Sedation in ICU | Loading 0.03–0.3 mg/kg in increments of 1–2.5 mg; maintenance 0.03–0.2 mg/kg/h | The label gives one figure spanning both adult columns |
Conscious sedation — how to give it
- "The dose must be individualised and titrated, and should not be administered by rapid or single bolus injection"1
- Give slowly — approximately 1 mg over 30 seconds
- In adults under 60: 2–2.5 mg given 5–10 minutes before the procedure, with further 1 mg doses as needed. "A total dose greater than 5 mg is usually not necessary"
- Onset of action is about 2 minutes; maximum effect at 5–10 minutes
Children
- Conscious sedation IV, 6 months–5 years: initial 0.05–0.1 mg/kg, total under 6 mg
- Conscious sedation IV, 6–12 years: initial 0.025–0.05 mg/kg, total under 10 mg
- Rectal, over 6 months: 0.3–0.5 mg/kg · IM, 1–15 years: 0.05–0.15 mg/kg
- ICU sedation: neonates <32 weeks 0.03 mg/kg/h; >32 weeks to 6 months 0.06 mg/kg/h; over 6 months loading 0.05–0.2 mg/kg then 0.06–0.12 mg/kg/h
Three strengths on one shelf
The same principle recurs elsewhere in this collection — calcium salts with three preparations at three different millimole contents, and noradrenaline labelled in both base and tartrate. Where a drug comes in multiple strengths, the strength is part of the dose.
Where it is used in emergency practice
- Procedural sedation — often with an opioid such as fentanyl, which markedly increases the risk of respiratory depression and requires the midazolam dose to be reduced
- Status epilepticus — buccal or intramuscular midazolam is first-line where intravenous access is not established, and is the standard community and paediatric route
- Acute behavioural disturbance — as part of rapid tranquillisation protocols, with monitoring
- Sedation of the ventilated patient, though propofol is generally preferred for its shorter offset
- As an induction agent — possible, but slower in onset and less predictable than propofol, ketamine or etomidate, and rarely the first choice for rapid sequence induction
Pharmacology
Mechanism
Midazolam binds the benzodiazepine site on the GABA-A receptor, increasing the frequency of chloride channel opening in response to GABA. The result is sedation, anxiolysis, anterograde amnesia, muscle relaxation and anticonvulsant activity — with no analgesic effect at all.
Kinetics
- Onset
- About 2 minutes; maximum effect 5–10 minutes
- Elimination half-life
- Short relative to other benzodiazepines — around 1.5–2.5 hours in health
- Metabolism
- Hepatic CYP3A4 to 1′-hydroxymidazolam — active, but contributing only about 10% of the effect of IV midazolam
- Accumulation
- Marked in renal impairment (active metabolite) and with prolonged infusion
Interactions
CYP3A4 inhibitors — clarithromycin, erythromycin, ketoconazole, ritonavir, diltiazem, grapefruit juice — substantially increase midazolam exposure. Inducers such as rifampicin and carbamazepine reduce it. Opioids, alcohol and other CNS depressants potentiate respiratory depression.
Reversal — and why you usually should not
Flumazenil is a competitive antagonist at the benzodiazepine site and will reverse midazolam sedation reliably. It has a genuine niche in exactly this situation — reversing iatrogenic over-sedation you administered yourself in a patient whose history you know and who is not benzodiazepine-dependent.
Adverse effects
- Respiratory depression and apnoea — dose-related, and greatly increased by concurrent opioids
- Hypotension, particularly in the elderly, the hypovolaemic and with rapid injection
- Paradoxical reactions — agitation, restlessness, hostility, involuntary movement; more common in children and the elderly
- Anterograde amnesia — usually desirable for a procedure, and a reason to give discharge information to a relative as well as to the patient
- Hiccup, nausea, vomiting
- Dependence and withdrawal with prolonged use
- Airway obstruction from loss of tone, in a patient who appears to be breathing adequately
Critical appraisal
- The age threshold is the most consequential and least remembered part of the label. Sixty is not a gentle taper — the SmPC halves the total and quarters the starting dose. Sedation-related deaths in older patients are disproportionately midazolam events, and this is why.
- Multiple strengths are an avoidable systems hazard. No pharmacological argument requires three concentrations to be available in the same department. Standardising is a cheap and effective intervention that many places have not made.
- Its role in procedural sedation has narrowed for good reasons. Propofol titrates more predictably and wears off faster; ketamine provides analgesia as well. Midazolam's amnesia remains genuinely valuable, but it is a slower, less controllable drug than the alternatives.
- Flumazenil is over-offered as a safety net. Its availability can encourage more liberal dosing on the assumption that reversal is straightforward. It is not — the half-life mismatch and the seizure risk mean the antidote is a poorer safeguard than careful titration.
References
- 1Midazolam 5mg/ml, solution for injection/infusion — Summary of Product Characteristics, hameln pharma ltd. electronic Medicines Compendium. Sections 4.1, 4.2, 4.4, 4.5, 4.8. Verified 24 Aug 2026. Compare the 1 mg/ml and 2 mg/ml presentations, emc and emc.
- 2Royal College of Emergency Medicine. Best Practice Guideline: Pharmacological Agents for Procedural Sedation and Analgesia in the Emergency Department. rcem.ac.uk
- 3National Institute for Health and Care Excellence. Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112). nice.org.uk
- 4National Patient Safety Agency. Rapid Response Report NPSA/2008/RRR011: Reducing risk of overdose with midazolam injection in adults. england.nhs.uk The alert behind UK restrictions on stocking high-strength midazolam outside critical care.
- 5Midazolam — dosing and safety monograph. BNF, NICE. bnf.nice.org.uk